SHR-1701 treatment for advanced lung cancer that cannot be surgically removed
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests SHR-1701, a new immunotherapy drug, combined with standard chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been newly diagnosed with advanced (stage III) non-small cell lung cancer that cannot be surgically removed
- You have not received any prior cancer treatment
- You do not have specific genetic mutations (EGFR, ALK, or ROS1) in your cancer
- You are in good enough health to tolerate treatment (ECOG score 0–1, meaning you can care for yourself and do light activities)
- You have no active autoimmune disease, uncontrolled infection, or uncontrolled high blood pressure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-1681 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug called SHR-1701 combined with a precise type of radiation (SBRT) for men with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this combination can help control the cancer.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This trial tests a new drug called SHR-A1811 in patients with advanced, incurable lung cancer that has a specific genetic change in the HER2 gene. The drug may help slow or stop cancer growth by targeting this genetic change.
This trial tests a new drug, SHR0302, combined with standard immunotherapy for people with advanced non-small cell lung cancer. It may be an option if you haven't had treatment yet or if your previous immunotherapy stopped working.
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
Hear when a new Chemoradiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.